Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure

Pediatr Infect Dis J. 2022 Feb 1;41(2):131-132. doi: 10.1097/INF.0000000000003364.

Abstract

We present a case report of a neonate receiving raltegravir-based postnatal HIV prophylaxis after in utero dolutegravir exposure. High levels of raltegravir and dolutegravir can potentially cause bilirubin toxicity as they compete for albumin binding and follow the same metabolic pathway through UGT1A1. This case suggests delaying initiation of raltegravir-based postnatal prophylaxis by 24-48 hours after in utero dolutegravir exposure.

Publication types

  • Case Reports

MeSH terms

  • Anti-HIV Agents* / administration & dosage
  • Anti-HIV Agents* / pharmacokinetics
  • Anti-HIV Agents* / therapeutic use
  • Antibiotic Prophylaxis*
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / prevention & control
  • Heterocyclic Compounds, 3-Ring / pharmacokinetics
  • Heterocyclic Compounds, 3-Ring / therapeutic use*
  • Humans
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical / prevention & control
  • Maternal Exposure
  • Oxazines / pharmacokinetics
  • Oxazines / therapeutic use*
  • Piperazines / pharmacokinetics
  • Piperazines / therapeutic use*
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Pyridones / pharmacokinetics
  • Pyridones / therapeutic use*
  • Raltegravir Potassium* / administration & dosage
  • Raltegravir Potassium* / therapeutic use

Substances

  • Anti-HIV Agents
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • Raltegravir Potassium
  • dolutegravir